Fludarabine
- Generic Name
- Fludarabine
- Brand Names
- Fludara
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12FN5O4
- CAS Number
- 21679-14-1
- Unique Ingredient Identifier
- P2K93U8740
- Background
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
- Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
- Associated Conditions
- B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Early Phase 1
Completed
- Conditions
- Primary MyelofibrosisSecondary Myelofibrosis
- Interventions
- Drug: CyclophosphamideBiological: FilgrastimDrug: Fludarabine PhosphateProcedure: Hematopoietic Cell TransplantationDrug: MelphalanDrug: Mycophenolate MofetilDrug: TacrolimusRadiation: Total-Body Irradiation
- First Posted Date
- 2018-02-08
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT03426969
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase 2
Recruiting
- Conditions
- Non-Small Cell Lung CancerBreast CancerOvarian CancerGastrointestinal/Genitourinary CancersEndocrine TumorsNeuroendocrine TumorsMultiple Myeloma
- Interventions
- Drug: CyclophosphamideDrug: FludarabineDrug: AldesleukinBiological: Individual Patient TCR-Transduced PBLDrug: Pembrolizumab (KEYTRUDA )
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 270
- Registration Number
- NCT03412877
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian
Phase 2
- Conditions
- Metastatic Ovarian Cancer
- Interventions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT03412526
- Locations
- 🇮🇱
Sheba medical Center, Ramat Gan, Israel
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
Phase 2
Recruiting
- Conditions
- Acute Biphenotypic LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveHematopoietic and Lymphoid Cell NeoplasmAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeMyelodysplastic Syndrome With Excess Blasts
- Interventions
- Biological: DilanubicelDrug: CyclophosphamideDrug: FludarabineDrug: ThiotepaRadiation: Total-Body IrradiationProcedure: Umbilical Cord Blood TransplantationOther: Laboratory Biomarker AnalysisProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirateProcedure: Bone Marrow BiopsyProcedure: Multigated Acquisition ScanProcedure: ElectrocardiographyProcedure: Computed Tomography
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT03399773
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
Phase 1
Terminated
- Conditions
- Myxoid/Round Cell LiposarcomaMultiple MyelomaMelanomaSynovial Sarcoma
- Interventions
- Biological: NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1Drug: CyclophosphamideDrug: FludarabineDevice: NY-ESO-1 expression testing
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 3
- Registration Number
- NCT03399448
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
Phase 1
Completed
- Conditions
- Myelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Relapsed Adult Acute MyeloidMyelodysplastic Syndromes, Previously Treated
- Interventions
- Drug: CPX-351Drug: FludarabineDrug: MelphalanDrug: Rabbit Anti-Human T-Lymphocyte GlobulinBiological: Haplo-Cord Stem Cell Transplantation
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 14
- Registration Number
- NCT03393611
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Phase 3
Completed
- Conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
- Drug: Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.Biological: Axicabtagene CiloleucelDrug: CyclophosphamideDrug: Fludarabine
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 359
- Registration Number
- NCT03391466
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML
Phase 3
- Conditions
- High Risk Acute Myeloid LeukemiaAllogeneic Hematopoeitic Stem Cell Transplantation
- Interventions
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 120
- Registration Number
- NCT03384212
- Locations
- 🇨🇳
Shanghai general hospital, Shanghai Jiaotong university school of medicine, Shanghai, Shanghai, China
CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML
Phase 3
- Conditions
- Allogeneic Hematopoeitic Stem Cell TransplantationHigh Risk Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 120
- Registration Number
- NCT03384225
- Locations
- 🇨🇳
Shanghai general hospital, Shanghai Jiaotong university school of medicine, Shanghai, Shanghai, China
Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma
Not Applicable
- Conditions
- Refractory or Relapsed Multiple Myeloma
- Interventions
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 6
- Registration Number
- NCT03380039
- Locations
- 🇨🇳
Xin Hua Hospital of Shanghai Jiao Tong University of Medicine, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath